JP2007520564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520564A5 JP2007520564A5 JP2006552252A JP2006552252A JP2007520564A5 JP 2007520564 A5 JP2007520564 A5 JP 2007520564A5 JP 2006552252 A JP2006552252 A JP 2006552252A JP 2006552252 A JP2006552252 A JP 2006552252A JP 2007520564 A5 JP2007520564 A5 JP 2007520564A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- use according
- ccx
- subject
- ckr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 229940124346 antiarthritic agent Drugs 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54184904P | 2004-02-03 | 2004-02-03 | |
| US60/541,849 | 2004-02-03 | ||
| US59895804P | 2004-08-04 | 2004-08-04 | |
| US60/598,958 | 2004-08-04 | ||
| US62619504P | 2004-11-08 | 2004-11-08 | |
| US60/626,195 | 2004-11-08 | ||
| PCT/US2005/003521 WO2005074645A2 (en) | 2004-02-03 | 2005-02-02 | Methods and compositions for modulating angiogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007520564A JP2007520564A (ja) | 2007-07-26 |
| JP2007520564A5 true JP2007520564A5 (cg-RX-API-DMAC7.html) | 2008-03-27 |
| JP4916889B2 JP4916889B2 (ja) | 2012-04-18 |
Family
ID=34841735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552252A Expired - Fee Related JP4916889B2 (ja) | 2004-02-03 | 2005-02-02 | 血管新生を調節するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050214287A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1715892A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4916889B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005209921B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2554880A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL177104A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005074645A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006038989A1 (en) * | 2004-09-29 | 2006-04-13 | Chemocentryx, Inc. | Substituted arylamides |
| AU2006263657A1 (en) * | 2005-06-29 | 2007-01-04 | Chemocentryx, Inc. | Substituted N-cinnamyl benzamides |
| US8088895B2 (en) * | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| JP2009091339A (ja) * | 2007-10-12 | 2009-04-30 | Seikagaku Kogyo Co Ltd | 関節リウマチの処置剤 |
| US8853202B2 (en) * | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
| US20110014121A1 (en) * | 2008-11-04 | 2011-01-20 | Chemocentryx, Inc. | Modulators of cxcr7 |
| CA2742515C (en) * | 2008-11-04 | 2017-07-11 | Chemocentryx, Inc. | 1,4-diazepane modulators of cxcr7 |
| US20120045393A1 (en) | 2009-03-17 | 2012-02-23 | Linder Karen E | Lhrh-ii peptide analogs |
| MX359651B (es) | 2012-11-29 | 2018-10-05 | Chemocentryx Inc | Antagonistas de cxcr7. |
| MX2021006915A (es) | 2018-12-12 | 2021-08-24 | Chemocentryx Inc | Inhibidores de cxcr7 para el tratamiento de cancer. |
| CN111593022B (zh) * | 2018-12-27 | 2023-10-24 | 广州溯原生物科技股份有限公司 | vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用 |
| EP4326257A4 (en) | 2021-04-19 | 2025-03-12 | ChemoCentryx, Inc. | AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020166133A1 (en) * | 1998-02-10 | 2002-11-07 | Millennium Pharmaceuticals, Inc | Neokine protein and nucleic acid molecules and uses therefor |
| JP2002506830A (ja) * | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
| US20020107195A1 (en) * | 1998-07-21 | 2002-08-08 | Smithkline Beecham Corporation | Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha |
| DE60137435D1 (de) * | 2000-09-15 | 2009-03-05 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| US20040157818A1 (en) * | 2001-05-24 | 2004-08-12 | Mikiro Yanaka | Cxcr4-antagonistic drugs composed of nitrogen-containing compound |
| US7253007B2 (en) * | 2001-11-30 | 2007-08-07 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| KR101061352B1 (ko) * | 2002-12-20 | 2011-08-31 | 케모센트릭스 | 인간 종양-발현된 ｃｃｘｃｋｒ2의 저해물질 |
| WO2004062591A2 (en) * | 2003-01-06 | 2004-07-29 | Oregon Health And Science University | Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases |
-
2005
- 2005-02-02 WO PCT/US2005/003521 patent/WO2005074645A2/en not_active Ceased
- 2005-02-02 AU AU2005209921A patent/AU2005209921B2/en not_active Ceased
- 2005-02-02 CA CA002554880A patent/CA2554880A1/en not_active Abandoned
- 2005-02-02 US US11/050,345 patent/US20050214287A1/en not_active Abandoned
- 2005-02-02 JP JP2006552252A patent/JP4916889B2/ja not_active Expired - Fee Related
- 2005-02-02 EP EP05726389A patent/EP1715892A4/en not_active Withdrawn
-
2006
- 2006-07-26 IL IL177104A patent/IL177104A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Folkman | Role of angiogenesis in tumor growth and metastasis | |
| JP2007520564A5 (cg-RX-API-DMAC7.html) | ||
| JP2010500360A5 (cg-RX-API-DMAC7.html) | ||
| CN102596216B (zh) | 鼻炎治疗剂 | |
| JP2007536311A5 (cg-RX-API-DMAC7.html) | ||
| WO2001027079A3 (en) | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease | |
| JP2022188083A5 (cg-RX-API-DMAC7.html) | ||
| BR9914360A (pt) | N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5 | |
| HRP20200117T1 (hr) | Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba | |
| EA200100799A1 (ru) | Антагонисты фактора опухолевого некроза и их применение при эндометриозе | |
| JP2022523530A5 (cg-RX-API-DMAC7.html) | ||
| RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| EP2167038B1 (en) | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus | |
| ZA202204624B (en) | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same | |
| Choi | New antiresorptive therapies for postmenopausal osteoporosis | |
| Tian et al. | Combination of radiofrequency ablation with resiquimod to treat hepatocellular carcinoma via inflammation of tumor immune microenvironment and suppression of angiogenesis | |
| Szatmary et al. | The role of cytokines and inflammation in the genesis of experimental pancreatitis | |
| Wang et al. | Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy‐induced ventricular remodelling and dysfunction | |
| JP2006511471A5 (cg-RX-API-DMAC7.html) | ||
| Shu et al. | The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma | |
| Cheung et al. | In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations | |
| ES2657949T3 (es) | KGF/FGF7 para uso en el tratamiento de la atrofia vaginal inducida por la quimioterapia | |
| Malaviya et al. | Targeting tumor necrosis factor alpha to mitigate lung injury induced by mustard vesicants and radiation | |
| Oratz et al. | Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma | |
| KR20180052761A (ko) | T-dm1 불응성 암 환자의 syd985 치료 |